Antithrombin Market

Date: 2016-05

Antithrombin, also known as Antithrombin III is a protien present in human blood that acts as an anticoagulant or blood thinner. The presence of antithrombin in the blood stream is extremely critical as it helps to prevent clotting of blood. Defeciency or low levels of antithrombin can lead to higher rate of clotting and excess of antithrombin can result in excessive bleeding. Thrombosis is a medical condition resulting from a low level of antithrombin that results in the obstruction of blood flow owing to the clots formed in the blood vessels. These clots can sometimes form even in the absence of an injury and also have the tendency to break free and travel through the blood vessels. This condition is known as thromboembolism.

There are two types of antithrombin defeciencies, namely, type I and type II. Inadequate amount of antithrombin is called type I and type II is associated with normal levels of antithrombin but reduced activity levels in case of affected patients聮 blood. Blood clotting is associated with symptoms such as fainting, swollen legs or feet, increased heart rate, shortness of breath, among others. Antithrombin defenciency could either be acquired or inherited. Inherited antithrombin defeciency is a rare occurrence and only a maximum of 0.2% of the population has it. One of the most popular drugs for treatment of antithrombin defeciency available on the market is ATryn, developed by rEVO Biologics and received the FDA approval in 2009.

Antithrombin Market

In terms of applications, the Antithrombin market has been segmented across the following:
Dry Chemistry
Monoclonal and Polyclonal antibodies
Chromogenic Substrates
DNA Probes
Artificial Intelligence

Asia Pacific is expected to exhibit the highest growth rate in the antrithrombin market throughout the forecast period considered in this report. This is attributed to the increasing popualtion in this region. However, in terms of market share, North America and Europe account for the largest share and will maintain this position till the end of the forecast period.

The market has been segmented based on the following geographies:
North America
South America
Middle East

A significant amount of consolidation has been taking placed in the global antithrombin market.
Following are just a few of the companies that are operating in the Antithrombin market:
Thermo Fisher Scientific Inc
Abott Laboratories
Siemens AG
American Diagnostica GmbH
Trinity Biotech


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample